Search company, investor...

Predict your next investment

Leerink Partners company logo
Investment Bank
FINANCE | Investment Banking
leerink.com

Investments

29

Portfolio Exits

17

Funds

5

Service Providers

1

About Leerink Partners

Leerink Partners is an investment bank with a focus on serving innovation-driven and growth-minded companies in the healthcare and life science sectors. The company offers a broad suite of financial solutions including M&A advisory, equity and debt capital markets, proprietary research, and comprehensive sales and trading capabilities. It primarily serves the healthcare industry, including sectors such as biopharma, digital health and healthtech, healthcare services, medical technology, and tools and diagnostics. The company was founded in 1995 and is based in Boston, Massachusetts.

Headquarters Location

53 State Street 40th Floor

Boston, Massachusetts, 02109,

United States

617-918-4000

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Leerink Partners News

Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares

Dec 7, 2023

Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares December 07, 2023 at 07:01 am EST Share CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about December 11, 2023, subject to customary closing conditions. J.P. Morgan and Leerink Partners are acting as joint book-running managers for the offering. Mizuho and Truist Securities are acting as book-runners and H.C. Wainwright & Co. and Raymond James are acting as co-managers for the offering. The offering is being made only by means of a prospectus and related prospectus supplement forming part of a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”). The preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC on December 6, 2023. The final prospectus supplement and the accompanying prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov, copies of which may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; or from Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding the closing of the public offering of ordinary shares. These statements are subject to various risks and uncertainties, actual results could differ materially from those projected and Wave cautions investors not to place undue reliance on the forward-looking statements in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to satisfaction of customary closing conditions related to the public offering. There can be no assurance that Wave will be able to complete the public offering on the anticipated terms, or at all. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s preliminary prospectus supplement related to the proposed offering filed with the SEC on December 6, 2023 and Wave’s most recent Annual Report on Form 10-K filed with the SEC, as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. Investor Contact: Wave Life Sciences Ltd. is a clinical-stage genetic medicines company. The Company is engaged in developing medicines across multiple therapeutic modalities using PRISM, its proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. The Company's ribonucleic acid (RNA)-targeting oligonucleotides is designed to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. Its lead programs are designed to treat genetic diseases, including those in muscle, including Duchenne muscular dystrophy (DMD); liver, including alpha-1 antitrypsin deficiency (AATD); and the central nervous system (CNS), including Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These programs include WVE-N531, WVE-006, WVE-003, and WVE-004. Sector

Leerink Partners Investments

29 Investments

Leerink Partners has made 29 investments. Their latest investment was in Odyssey Therapeutics as part of their Series C on December 12, 2023.

CBI Logo

Leerink Partners Investments Activity

investments chart

Leerink Partners Portfolio Exits

17 Portfolio Exits

Leerink Partners has 17 portfolio exits. Their latest portfolio exit was Vera Whole Health on July 01, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/1/2021

Acq - Fin

$99M

2

3/22/2021

Acquired

$99M

8

12/3/2020

IPO

$99M

Public

11

7/30/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/12/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/1/2021

3/22/2021

12/3/2020

7/30/2020

6/12/2020

Exit

Acq - Fin

Acquired

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

2

8

11

10

10

Leerink Partners Fund History

5 Fund Histories

Leerink Partners has 5 funds, including Leerink Revelation Partners Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/12/2018

Leerink Revelation Partners Fund II

$227M

1

9/29/2017

Health IT Growth Equity Fund I

$99M

10

7/6/2016

Leerink Transformation Fund I

$99M

10

6/11/2015

LEERINK Revelation Partners

$99M

10

Massachusetts Innovation Catalyst Fund

10

Closing Date

6/12/2018

9/29/2017

7/6/2016

6/11/2015

Fund

Leerink Revelation Partners Fund II

Health IT Growth Equity Fund I

Leerink Transformation Fund I

LEERINK Revelation Partners

Massachusetts Innovation Catalyst Fund

Fund Type

Status

Amount

$227M

$99M

$99M

$99M

Sources

1

10

10

10

10

Leerink Partners Service Providers

1 Service Provider

Leerink Partners has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Leerink Partners Team

22 Team Members

Leerink Partners has 22 team members, including current Chief Executive Officer, Jeffrey A. Leerink.

Name

Work History

Title

Status

Jeffrey A. Leerink

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Jeffrey A. Leerink

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.